Matches in SemOpenAlex for { <https://semopenalex.org/work/W3039521618> ?p ?o ?g. }
- W3039521618 endingPage "2001890" @default.
- W3039521618 startingPage "2001890" @default.
- W3039521618 abstract "Acute myeloid leukemia (AML) is the most common adult acute leukemia with very low survival rate due to drug resistance and high relapse rate. The C-X-C chemokine receptor 4 (CXCR4) is highly expressed by AML cells, actively mediating chemoresistance and reoccurrence. Herein, a chemically synthesized CXCR4 antagonistic peptide E5 is fabricated to micelle formulation (M-E5) and applied to refractory AML mice, and its therapeutic effects and pharmacokinetics are investigated. Results show that M-E5 can effectively block the surface CXCR4 in leukemic cells separated from bone marrow (BM) and spleen, and inhibit the C-X-C chemokine ligand 12-mediated migration. Subcutaneous administration of M-E5 significantly inhibits the engraftment of leukemic cells in spleen and BM, and mobilizes residue leukemic cells into peripheral blood, reducing organs' burden and significantly prolonging the survival of AML mice. M-E5 can also increase the efficacy of combining regime of homoharringtonine and doxorubicin. Ribonucleic acid sequencing demonstrates that the therapeutic effect is contributed by inhibiting proliferation and enhancing apoptosis and differentiation, all related to the CXCR4 signaling blockade. M-E5 reaches the concentration peak at 2 h after administration with a half-life of 14.5 h in blood. In conclusion, M-E5 is a novel promising therapeutic candidate for refractory AML treatment." @default.
- W3039521618 created "2020-07-10" @default.
- W3039521618 creator A5000797890 @default.
- W3039521618 creator A5012931311 @default.
- W3039521618 creator A5013038112 @default.
- W3039521618 creator A5015102287 @default.
- W3039521618 creator A5017482227 @default.
- W3039521618 creator A5026171887 @default.
- W3039521618 creator A5029695574 @default.
- W3039521618 creator A5035677923 @default.
- W3039521618 creator A5038779010 @default.
- W3039521618 creator A5056049949 @default.
- W3039521618 creator A5060165452 @default.
- W3039521618 creator A5065543394 @default.
- W3039521618 creator A5067006313 @default.
- W3039521618 creator A5086214965 @default.
- W3039521618 creator A5091284530 @default.
- W3039521618 date "2020-06-30" @default.
- W3039521618 modified "2023-10-11" @default.
- W3039521618 title "Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia" @default.
- W3039521618 cites W1520462246 @default.
- W3039521618 cites W154306038 @default.
- W3039521618 cites W1548997088 @default.
- W3039521618 cites W1561964696 @default.
- W3039521618 cites W1985902169 @default.
- W3039521618 cites W2000980282 @default.
- W3039521618 cites W2010193429 @default.
- W3039521618 cites W2023624246 @default.
- W3039521618 cites W2030034265 @default.
- W3039521618 cites W2034297853 @default.
- W3039521618 cites W2039964437 @default.
- W3039521618 cites W2043046186 @default.
- W3039521618 cites W2053339285 @default.
- W3039521618 cites W2054353525 @default.
- W3039521618 cites W2060497614 @default.
- W3039521618 cites W2083774639 @default.
- W3039521618 cites W2085328048 @default.
- W3039521618 cites W2090311885 @default.
- W3039521618 cites W2091552147 @default.
- W3039521618 cites W2110279746 @default.
- W3039521618 cites W2115899473 @default.
- W3039521618 cites W2125251487 @default.
- W3039521618 cites W2126283967 @default.
- W3039521618 cites W2127789926 @default.
- W3039521618 cites W2128532174 @default.
- W3039521618 cites W2128645075 @default.
- W3039521618 cites W2132055765 @default.
- W3039521618 cites W2140382736 @default.
- W3039521618 cites W2145483241 @default.
- W3039521618 cites W2149888039 @default.
- W3039521618 cites W2158737833 @default.
- W3039521618 cites W2162956874 @default.
- W3039521618 cites W2162995424 @default.
- W3039521618 cites W2163065691 @default.
- W3039521618 cites W2166446553 @default.
- W3039521618 cites W2179176827 @default.
- W3039521618 cites W2202126706 @default.
- W3039521618 cites W2380791235 @default.
- W3039521618 cites W2405289692 @default.
- W3039521618 cites W2461928138 @default.
- W3039521618 cites W2554773181 @default.
- W3039521618 cites W2561193801 @default.
- W3039521618 cites W2563163577 @default.
- W3039521618 cites W2593366005 @default.
- W3039521618 cites W2605743022 @default.
- W3039521618 cites W2613279617 @default.
- W3039521618 cites W2764273516 @default.
- W3039521618 cites W2767714545 @default.
- W3039521618 cites W2774461834 @default.
- W3039521618 cites W2779543239 @default.
- W3039521618 cites W2792676100 @default.
- W3039521618 cites W2800234877 @default.
- W3039521618 cites W2811180866 @default.
- W3039521618 cites W2885133494 @default.
- W3039521618 cites W2892491493 @default.
- W3039521618 cites W2896480326 @default.
- W3039521618 cites W2915288283 @default.
- W3039521618 cites W2975143710 @default.
- W3039521618 cites W3006187966 @default.
- W3039521618 cites W4247555556 @default.
- W3039521618 doi "https://doi.org/10.1002/smll.202001890" @default.
- W3039521618 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32608185" @default.
- W3039521618 hasPublicationYear "2020" @default.
- W3039521618 type Work @default.
- W3039521618 sameAs 3039521618 @default.
- W3039521618 citedByCount "15" @default.
- W3039521618 countsByYear W30395216182021 @default.
- W3039521618 countsByYear W30395216182022 @default.
- W3039521618 countsByYear W30395216182023 @default.
- W3039521618 crossrefType "journal-article" @default.
- W3039521618 hasAuthorship W3039521618A5000797890 @default.
- W3039521618 hasAuthorship W3039521618A5012931311 @default.
- W3039521618 hasAuthorship W3039521618A5013038112 @default.
- W3039521618 hasAuthorship W3039521618A5015102287 @default.
- W3039521618 hasAuthorship W3039521618A5017482227 @default.
- W3039521618 hasAuthorship W3039521618A5026171887 @default.
- W3039521618 hasAuthorship W3039521618A5029695574 @default.
- W3039521618 hasAuthorship W3039521618A5035677923 @default.